ASCO Poster

A cost-effectiveness analysis of palbociclib plus letrozole as first-line treatment for estrogen receptor-positive, HER2-negative, metastatic breast cancer.Klazien Matter-Walstra, Matthias Schwenkglenks, Peter Brauchli, Dirk Klingbiel, Konstantin J. Dedes;J Clin Oncol 34, 2016 (suppl; abstr 567)

Kommentar schreiben

Kommentare: 0

Fr

16

Apr

2021

Vorbereitungen R├╗zje Wyn 2021

Sa

24

Okt

2020

Kroatien 2020

Sa

23

Mai

2020

Arc-en-ciel

Thanks to Saskia and Patrick for these recordings

mehr lesen